HOME > ドクター紹介

院長メッセージ

シゲトウクリニック院長 糖尿病専門医 医学博士 重藤 誠 生活の欧米化に伴い、我が国でも肥満が社会問題となっています。肥満は高血圧、糖尿病などの生活習慣病のみならず、脳卒中、心筋梗塞、がんなどとも関連しており、生活の質を大きく下げます。

早い段階から生活習慣に介入することで、より効率的な将来の医療費抑制が期待できますが、十分な予防ができているとは言い難いのが現状です。

自然に食欲を落として体重を減らすGLP-1は、美容上のメリットが得られるだけでなく、様々な病気を予防することができ、結果的に健康寿命を延ばすことも期待できます。

空腹感を我慢したり、ハードなトレーニングで体に負担をかけたり、食事のたびにカロリー計算をしたり、毎日体重計に乗ってその数値に一喜一憂する必要のない新しいダイエットですので、これまで食欲を抑えられずにダイエットとリバウンドを繰り返してきた方、ダイエットを諦めていた方々にも、効果を実感していただいております。

糖尿病専門医の提供する当院の治療は、非専門家が行う危険性の高い方法で健康を害したりしている方々の助けになるはずです。

皆様の健康に貢献できるよう、スタッフ一同努力してまいります。

シゲトウクリニック院長 糖尿病専門医 医学博士
 重藤 誠

院長経歴・ 資格・所属団体

経歴

2001年
川崎医科大学卒業
2001年
京都府立医科大学附属病院第3内科
2002年
市立福知山市民病院内科
2003年
川崎医科大学糖尿病内分泌内科
2007年
亀田総合病院糖尿病内分泌内科
2009年
医学博士取得
2009年
Oxford大学(Rorsman’s group)客員研究員
2011年
Oxford大学(Rorsman’s group)正研究員
2014年
Gothenburg大学(Rorsman’s group)正研究員
論文:Shigeto M et.al. (2015) GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation. The Journal of Clinical Investigation(インパクトファクター:12.784点)
2016年~
日本バプテスト病院糖尿病内科
2016年~
シゲトウクリニック開院院長
2016年~
滋賀医科大学客員講師

認定資格

  • ・日本内科学会認定内科医
  • ・日本糖尿病学会認定糖尿病専門医

所属団体

  • ・日本内科学会
  • ・日本糖尿病学会
  • ・日本内分泌学会
  • ・日本糖尿病、妊娠学会
オックスフォード大学からの招聘状 オックスフォード大学からの
招聘状
オックスフォード大学からのスポンサー証明 オックスフォード大学からの
スポンサー証明
筆頭著者論文 筆頭著者論文
滋賀医大客員講師の授与証明書 滋賀医大客員講師の授与
証明書

GLP-1に関する研究発表

1.ShigetoM, Cha CY, RorsmanP, et al. A role of PLC/PKC dependent pathway in GLP-1 stimulated insulin J MolMed. (In press)

2. ShigetoM, RamracheyaR, Tarasov AI, et al. GLP-1stimulates insulin secretion by PKC-dependent TRPM4 TRPM5 activation. J ClinInvest. 1;125(12):4714-28. 2015

3. ShigetoM, KakuK. Are both protein kinase A-and protein kinase C-dependent pathways involved in peptide-1 action on pancreatic insulin secretion? J Diabetes Investig.5(4):347-8. 2014.

4.Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K.: Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-protein kinase A pathway. J PharmacolSci. Nov;108(3):274-9.
1. ShigetoM, RamracheyaR, RorsmanN, et al. Physiological concentrationsof GLP-1increase insulin secretion activating protein kinase C pathway in pancreatic beta cellsl. (European Association for the Study of Diabetes 48th Annual Meeting, Berlin, Germany, 1 -5 OCT, 2012, 講演発表)

2. ShigetoM, RamracheyaR, BrahaO, et al. Low concentrationof GLP-1increase insulin secretion and current activating Protein kinase C pathway on pancreatic beta-cell. (European Association for the Study of (EASD), 47th Annual Meeting, Lisbon,Portugal,12 –16 SEP, 2011)

3. ShigetoM, KatsuraM, Matsuda M, etal.Low, but physiological, concentrationof GLP-1stimulates insulin independent of the cAMP-protein kinase A pathway. (European Association for the Study of Diabetes (EASD), Annual Meeting, Rome, Italy, 8 –11 SEP, 2008, 講演発表)
1. Shigeto M, Ramracheya R, Tarasov AI, Cha CY, Chibalina MV, Hastoy B, Philippaert K, Reinbothe T, Rorsman N, Salehi A, Sones WR, Vergari E, Weston C, Gorelik J, Katsura M, Nikolaev VO, Vennekens R, Zaccolo M, Galione A, Johnson PR, Kaku K, Ladds G, Rorsman P. GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation.JClinInvest. 1;125(12):4714-28. 2015

2. Shigeto M, Kaku K. Are both protein kinase A-and protein kinase C-dependent pathways involved in glucagon-like peptide-1 action on pancreatic insulin secretion? J Diabetes Investig.5(4):347-8. 2014.

3. Rosengren AH, Braun M, Mahdi T, Andersson SA, Travers ME, Shigeto M, Zhang E, Almgren P, Ladenvall C, Axelsson AS, Edlund A, Pedersen MG, Jonsson A, Ramracheya R, Tang Y, Walker JN, Barrett A, Johnson PR, Lyssenko V, McCarthy MI, Groop L, Salehi A, Gloyn AL, Renström E, Rorsman P, Eliasson L: Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes.Diabetes. 2012 Jul;61(7):1726-33.

4. Walker JN, Johnson PR, Shigeto M, Hughes SJ, Clark A, Rorsman P.: Glucose-responsive beta cells in islets isolated from a patient with long-standing type 1 diabetes mellitus. Diabetologia. 21, 2010.

5. Ramracheya R, Ward C, Shigeto M, Walker JN, Amisten S, Zhang Q, Johnson PR, RorsmanP, Braun M.: Membrane potential-dependent inactivation of voltage-gated ion channels in alpha-cells inhibits glucagon secretion from human islets. Diabetes. 59(9):2198-208. 2010

6. Kawasaki F, Kamei S, Tatsumi F, Hamamoto S, Shimoda M, Tawaramoto K, Shigeto M, Kanda Y, Hashiramoto M, Matsuki M, Kaku K.: Gallbladder edema in type 1 diabetic patient due to delayed-type insulin allergy. Intern Med. 2009;48(17):1545-9.

7. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K.: Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-protein kinase A pathway. J PharmacolSci. Nov;108(3):274-9.

8. Matsuki M, Matsuda M, Kohara K, Shimoda M, Kanda Y, Tawaramoto K, Shigeto M, Kawasaki F, Kotani K, Kaku K.: Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once-versus twice-daily dosing. EndocrJ. 2007 Aug;54(4):571-6.

9. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K.: Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J PharmacolExpTher. 2007 Jul;322(1):1-7.

10. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K.: First phase of glucose-stimulated insulin secretion from MIN 6 cells does not always require extracellular calcium influx. J PharmacolSci. 2006 Aug;101(4):293-302. Epub2006 Aug 5.

11. Saito M, Eto M, Nitta H, Kanda Y, Shigeto M, Nakayama K, Tawaramoto K, Kawasaki F, Kamei S, Kohara K, Matsuda M, Matsuki M, Kaku K.: Effect of apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients. Diabetes Care. 2004 Jun;27(6):1276-80.

12. KatsuraM, ShutoK, MohriY, ShigetoM, OhkumaS.: Functional significance of nitric oxide in ionomycin-evoked [3H]GABA release from mouse cerebral cortical neurons. J Neurochem. 2002 Apr;81(1):130-41.
1. Shigeto M, Hisano Y, Hayakawa N, Akiyama Y, Masuzawa M, Okabe T, Matsuda M: A case of type 1 diabetes mellitus suspect to coincident with the onset of drug-induced hepatitis one month after the AprindineHydrochloride administration. Japanese Journal of the Japan Diabetes Society [Tounyoubyou] 2009 Jan;52(1)

2. Shimoda S, Kamei S, Hamamoto S, Tawaramoto K, Shigeto M, Kanda Y, Kohara K, Matsuda M, Matuski M, Kaku K: Two casesofBasedow’sdisease with pulmonary hypertension. Hormone and Clinical Practice [Horumonto rinsyou] 56(2) 211-216 2008

3. Shimoda M, Hayakawa N, Tatsumi F, Tawaramoto K, Shigeto M, Kanda Y, Kawasaki F, Hashiramoto M, Matsuki M, and Kaku K: Efficacy of Low-dose Gliclazidein Patients with Type 2 Diabetes Previously Treated with Rapid-acting InsulinotropicAgent or Sulfonylurea other than GliclazideJapanese Journal of the Japan Diabetes Society [Tounyoubyou] 2008 Jan;51(3) 221-225.
1. Shigeto M: Molecular mechanisms of glucagon secretion (regulation in alpha cell). Japanese Journal of the Japan Diabetes Society [Tounyoubyou] 55(11):838-840,2012.

2. Shigeto M: Glucose monitoring during administration of steroid. Expert Nurse 28 (5) 104-109, 2012.

3. Shigeto M, Matsuda M: When to start pharmacological intervention in cases with HbA1C at around 8% Practical Diabetes Treatment. Medicina45(6):1005-1008, 2008.

4. Shigeto M, Matsuda M: DDP-IV inhibitor, New oral agents, New treatment of Diabetes Mellitus: Strategy of the management to accomplish the treatment target. Modern Physician 28 (2) 174-176 2008.

5. Shigeto M, Matsuda M: Why the upper limit of normal values have been settled as criteria for the diagnosis of metabolic syndrome? Practical Seminar of Metabolic Syndrome. Medical Practice 24 (9) 1559-1560,2007.

6. Shigeto M, Matsuda M: GLP-1 analogues, Basic and Clinical Science of GLP-1. Endocrine and Diabetes Department [NaibunpituTounyoubyouKa] 23 (3) 286-290, 2006.
1. Shigeto M, Ramracheya R, Rorsman N, Katsura M, Thorens B, Kaku K, Rorsman P : Physiological concentrations of GLP-1 increase insulin secretion by activating protein kinase C pathway in pancreatic beta cellsl. (The 48th Annual Meeting of the European Association for the Study of Diabetes, 1 -5 October, 2012)

2. Shigeto M, Ramracheya R, Braha O, Braun M, Katsura M, Kaku K, Rorsman P : Low concentration of GLP-1 increase insulin secretion and calcium current activating Protein kinase C pathway on pancreatic beta-cell. (The 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, 9/12 –16, 2011)

3. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K: Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-protein kinase A pathway. (The 44th Annual Meeting of the European Association for the Study of Diabetes, Rome, 9/7 –11, 2008) Diabetologia51(Suppl1):S113, 2008.

4. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K: First phase of glucose-stimulated insulin secretion from pancreasconsistsof three different pathways including ATP-sensitive potassium channel. (The 65th Scientific Sessions of American Diabetes Association, San Diego, 6/10-14, 2005) Diabetes 54(Suppl1):A407, 2005.

5. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K:ATP-sensitive potassium channel independent pathway is involved in action mechanism of meglitinides, but not sulfonylureas. (The 41st Annual Meeting of the European Association for the Study of Diabetes, Athens, Greece,9/10-15, 2005) Diabetologia48(Suppl1):A174, 2005.